Luvox is a brand-name medication that contains the active ingredient fluvoxamine, an antidepressant classified as a selective serotonin reuptake inhibitor (SSRI). It is supplied in pill form and is available in 50 mg and 100 mg strengths. In Hong Kong, Luvox is a prescription-only product and is regulated by the Hong Kong Department of Health. The medication is primarily indicated for certain anxiety-related disorders and works by modestly increasing serotonin levels in the brain.
Fluvoxamine belongs to the SSRI class. It blocks the serotonin transporter protein on presynaptic neurons, which reduces the re-absorption (reuptake) of serotonin back into the nerve cell. This results in higher concentrations of serotonin remaining in the synapse, enhancing serotonergic neurotransmission. The increased serotonin activity helps to normalize mood and anxiety pathways, which underlies its therapeutic effect in obsessive-compulsive and anxiety disorders. Onset of clinical benefit typically occurs within 2-4 weeks, with peak effects observed after several weeks of consistent dosing.
Luvox is approved in many regulatory regions, including Hong Kong, for the following indications:
These uses are supported by clinical trial data reviewed by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), and the approvals have been adopted by Hong Kong’s regulatory framework.
Evidence from peer-reviewed studies suggests that fluvoxamine may be beneficial for other conditions, although these uses are not formally approved:
Disclaimer: Off-label use requires medical supervision and an individualized risk assessment. Patients should discuss potential benefits and risks with a qualified healthcare professional.
This article provides educational information about Luvox and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Luvox may be taken at any time of day, but many patients prefer morning dosing to reduce the likelihood of insomnia. If night-time dosing is chosen, monitor for sleep disturbances and discuss any concerns with a pharmacist or physician.
If the missed dose is within a few hours, take it as soon as you remember. If it is close to the next scheduled dose, skip the missed tablet and continue with the regular dosing schedule. Doubling the dose is not recommended.
First-generation antihistamines (e.g., diphenhydramine) can increase drowsiness when combined with Luvox. Second-generation antihistamines (e.g., cetirizine) generally have a lower risk of interaction, but patients should still monitor for excessive sedation.
Fluvoxamine crosses the placenta and its safety in pregnancy has not been definitively established. It should only be used when the potential benefits outweigh the risks, and this decision must be made in consultation with an obstetrician.
Yes, but keep the medication in its original labelled container, carry a copy of the prescription, and store it in your hand luggage to avoid temperature extremes. Some countries may require a medical certificate for controlled medications.
In most markets, the 50 mg tablet is smaller and may be scored for splitting, while the 100 mg tablet is larger and typically unscored. The exact appearance can vary by manufacturer, so verify the imprint code on the packaging.
Luvox is not a prohibited substance in standard workplace drug screens. However, occupational health programs may request a medication list, and patients should disclose their use of Luvox when asked.
Steady-state concentrations are usually achieved after about 5 days of consistent dosing, reflecting its half-life of approximately 15-20 hours.
Weight changes are not a prominent side effect of fluvoxamine. Some patients may experience slight weight loss due to reduced appetite, while others report stable weight. Regular monitoring is advised if weight changes become a concern.
Direct switching between SSRIs can increase the risk of serotonin syndrome. A short washout period (typically 2-5 days) or a cross-taper strategy is often recommended, but the exact approach should be individualized by a prescriber.
